Literature DB >> 2083185

5-Fluorouracil cardiotoxicity: a critical review.

W J Gradishar1, E E Vokes.   

Abstract

5-Fluorouracil is a commonly administered chemotherapy agent that has infrequently been associated with cardiotoxicity. This review highlights the clinical features of this syndrome as described in reports from the medical literature. Clinical and laboratory evidence supporting proposed underlying mechanisms are reviewed.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2083185     DOI： 10.1093/oxfordjournals.annonc.a057793

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


  22 in total

1.  [Angina pectoris and ST-elevation after chemotherapy with 5-fluorouracil].

Authors:  S Spencker; A Schmittel; D Westermann; A Marek; H P Schultheiss; B Witzenbichler
Journal:  Internist (Berl)       Date:  2007-01       Impact factor: 0.743

Review 2.  Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics? (Review).

Authors:  Stella Baliou; Anthony M Kyriakopoulos; Demetrios A Spandidos; Vassilios Zoumpourlis
Journal:  Int J Oncol       Date:  2020-07-14       Impact factor: 5.650

Review 3.  Cardiotoxicity of the antiproliferative compound fluorouracil.

Authors:  K Becker; J F Erckenbrecht; D Häussinger; T Frieling
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 4.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

5.  Postoperative myocardial injury after major head and neck cancer surgery.

Authors:  Peter Nagele; Lesley K Rao; Mrudula Penta; Dorina Kallogjeri; Edward L Spitznagel; Laura F Cavallone; Brian Nussenbaum; Jay F Piccirillo
Journal:  Head Neck       Date:  2010-09-30       Impact factor: 3.147

Review 6.  Cardiotoxicity of cancer chemotherapy: implications for children.

Authors:  Valeriano C Simbre; Sarah A Duffy; Gul H Dadlani; Tracie L Miller; Steven E Lipshultz
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

7.  Comparison of 5-fluorouracil anabolite levels after intravenous bolus and continuous infusion.

Authors:  T A Stein; B Bailey; G P Burns
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.

Authors:  E E Vokes; S M O'Brien; N J Vogelzang; R L Schilsky; M J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Combination of daily 4-h infusion of 5-fluorouracil and cisplatin in the treatment of advanced head and neck squamous-cell carcinoma: a South-East European Oncology Group study.

Authors:  J Jassem; F Gyergyay; S Kerpel-Fronius; T Nagykálnai; J Baumöhl; J Verweij; L Vuletic; Z Mechl; M Drozd-Lula; S Jelic
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy.

Authors:  Raymond R Russell; Jonathan Alexander; Diwakar Jain; Indu G Poornima; Ajay V Srivastava; Eugene Storozynsky; Ronald G Schwartz
Journal:  J Nucl Cardiol       Date:  2016-06-01       Impact factor: 5.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.